spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Chiltern Acquires Japanese Clinical Research Organization Integrated Development Associates Co. Ltd.

Chiltern

Chiltern, a leading global contract research organization, has acquired Integrated Development Associates Co. Ltd. (IDA), a CRO specializing in integrating Japan and Asia into global drug development.

London, U.K., Wilmington, N.C. and Tokyo, Japan; May 31, 2017 (Business Wire)Chiltern, a leading global contract research organization, has acquired Integrated Development Associates Co. Ltd. (IDA), a CRO specializing in integrating Japan and Asia into global drug development.

With staff based in Japan, Korea and Southeast Asia, IDA has extensive expertise in establishing regulatory and development pathways for Japan and implementing Pan Asian clinical trials to achieve both Japanese and global regulatory objectives. IDA’s experience in a broad range of therapeutic areas and its local knowledge and relationships will allow Chiltern to offer optimal approaches for integrating Japan and Asia into global drug development. In addition, the acquisition opens opportunities for Japanese companies to enter a wider market by relying on Chiltern’s global expertise and connections. 

“The acquisition of IDA is driven by our commitment to establish a substantial presence in all major global markets and support our clients with clinical development capabilities worldwide,” said Jim Esinhart, Ph.D., Chiltern CEO. “Japan and Southeast Asia are among the world’s largest and fastest-growing pharmaceutical markets. IDA will enable us to grow in the APAC region through well-established relationships and local expertise and knowledge.”

IDA will do business as a wholly owned subsidiary of Chiltern and be renamed IDA, a Chiltern Company. As a part of this agreement, IDA’s founder and CEO, John Winebarger, will continue to lead IDA. Winebarger has more than 30 years’ experience working in Japan and will join Chiltern’s leadership team.

To learn more about Chiltern’s global clinical development services, visit Chiltern.com.

About Chiltern

Chiltern, a global contract research organization, is a leading provider of clinical services and solutions in a variety of therapeutic areas with engagement models for biopharmaceutical and medical device industries. Chiltern’s team of more than 4,300, located across 47 countries, provides comprehensive Clinical Development, Medical & Scientific Affairs, Data & Analysis, Pharmacovigilance and Strategic Regulatory services using a collaborative approach for more efficient clinical trials. Visit Chiltern.com to learn more about how Chiltern is Designed Around You®.
phone UK:+44(0)1753 512 000; US:+1 (423) 968 9533
email info@chiltern.com
web www.chiltern.com
email UK: 171 Bath Road, Slough, Berkshire, SL1 4AA. US: 3147 S. 17th Street, Suite 300 Wilmington, NC 28412.
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZeneca’s (NYSE: AZN) high-throughput screening (HTS) and compound management infrastructure. Through the agreement, Charles River will perform HTS programs for its clients utilizing AstraZeneca’s state-of-the-art HTS facility.
More info >>


White Papers

Pharmaceutical Companies: Outsourcing Combination Product Manufacturing

Phillips-Medisize

Combination products are therapeutics that combine two or more products (drug/device, biologics/device, biologics/drugs, or drug/device/biologics), regulated and sold as a single unit. Examples of combination products include drug-coated implantable devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
More info >>

Industry Events

PHARM Connect Congress 2018

13-14 March 2018, Corinthia Hotel Budapest, Hungary

PHARM Connect Congress is the premier networking business event dedicated to pharmaceutical and biotechnology innovations and trends from development through commercialization in Central and Eastern Europe and the CIS region. The two days event offers the perfect setting for solution providers to present their products and services directly to key decision makers playing a key role in the pharmaceutical industry in Central Eastern Europe.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement